Andrejs Erglis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4310452/publications.pdf

Version: 2024-02-01

171 papers	16,740 citations	41344 49 h-index	15266 126 g-index
174 all docs	174 docs citations	174 times ranked	13767 citing authors

#	Article	IF	Citations
1	Diagnostic Performance of Noninvasive Fractional Flow Reserve Derived From CoronaryÂComputed Tomography Angiography in Suspected Coronary Artery Disease. Journal of the American College of Cardiology, 2014, 63, 1145-1155.	2.8	1,240
2	Diagnosis of Ischemia-Causing Coronary Stenoses by Noninvasive Fractional Flow Reserve Computed From Coronary Computed Tomographic Angiograms. Journal of the American College of Cardiology, 2011, 58, 1989-1997.	2.8	1,058
3	Diagnostic Accuracy of Fractional Flow Reserve From Anatomic CT Angiography. JAMA - Journal of the American Medical Association, 2012, 308, 1237.	7.4	956
4	EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. European Journal of Preventive Cardiology, 2016, 23, 636-648.	1.8	772
5	Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. New England Journal of Medicine, 2017, 376, 1824-1834.	27.0	742
6	European Society of Cardiology: Cardiovascular Disease Statistics 2019. European Heart Journal, 2020, 41, 12-85.	2.2	690
7	Randomized Study on Simple Versus Complex Stenting of Coronary Artery Bifurcation Lesions. Circulation, 2006, 114, 1955-1961.	1.6	666
8	Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet, The, 2016, 388, 2743-2752.	13.7	620
9	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. European Journal of Preventive Cardiology, 2019, 26, 824-835.	1.8	558
10	Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. Circulation, 2015, 131, 54-61.	1.6	552
11	European Society of Cardiology Heart Failure Longâ€Term Registry (<scp>ESCâ€HFâ€LT</scp>): 1â€year followâ€up outcomes and differences across regions. European Journal of Heart Failure, 2016, 18, 613-625.	7.1	538
12	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2013, 15, 1173-1184.	7.1	533
13	Sirolimus-Eluting versus Uncoated Stents in Acute Myocardial Infarction. New England Journal of Medicine, 2006, 355, 1093-1104.	27.0	523
14	A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. European Heart Journal, 2018, 39, 2484-2493.	2.2	380
15	Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures. European Heart Journal, 2012, 33, 2513-2520.	2.2	349
16	Novel Baroreflex Activation Therapy in Resistant Hypertension. Journal of the American College of Cardiology, 2010, 56, 1254-1258.	2.8	321
17	Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. Lancet, The, 2020, 395, 191-199.	13.7	280
18	Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. European Heart Journal, 2014, 35, 1957-1970.	2.2	275

#	Article	IF	Citations
19	Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ: British Medical Journal, 2008, 337, a1331-a1331.	2.3	270
20	Randomized Comparison of Final Kissing Balloon Dilatation Versus No Final Kissing Balloon Dilatation in Patients With Coronary Bifurcation Lesions Treated With Main Vessel Stenting. Circulation, 2011, 123, 79-86.	1.6	269
21	Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study. Lancet, The, 2019, 394, 1629-1637.	13.7	263
22	Atherosclerotic Plaque Characteristics byÂCT Angiography Identify Coronary Lesions That Cause Ischemia. JACC: Cardiovascular Imaging, 2015, 8, 1-10.	5.3	241
23	Noninvasive Fractional Flow Reserve Derived From Computed Tomography Angiography for Coronary Lesions of Intermediate Stenosis Severity. Circulation: Cardiovascular Imaging, 2013, 6, 881-889.	2.6	218
24	A prospective, randomized trial of intravascular-ultrasound guided compared to angiography guided stent implantation in complex coronary lesions: The AVIO trial. American Heart Journal, 2013, 165, 65-72.	2.7	212
25	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 618-628.	11.4	207
26	Long-Term Results After Simple Versus Complex Stenting of Coronary Artery Bifurcation Lesions. Journal of the American College of Cardiology, 2013, 62, 30-34.	2.8	168
27	Randomized Comparison of Coronary Bifurcation Stenting With the Crush Versus the Culotte Technique Using Sirolimus Eluting Stents. Circulation: Cardiovascular Interventions, 2009, 2, 27-34.	3.9	156
28	Simple or Complex Stenting for Bifurcation Coronary Lesions. Circulation: Cardiovascular Interventions, 2011, 4, 57-64.	3.9	152
29	A Novel Noninvasive Technology for Treatment Planning Using Virtual Coronary Stenting and Computed Tomography-Derived Computed Fractional Flow Reserve. JACC: Cardiovascular Interventions, 2014, 7, 72-78.	2.9	144
30	Drug-Eluting Stent for Left Main Coronary Artery Disease. JACC: Cardiovascular Interventions, 2012, 5, 718-727.	2.9	121
31	Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Circulation, 2021, 144, 1476-1484.	1.6	121
32	Safety of the Deferral of Coronary Revascularization on the Basis of Instantaneous Wave-Free Ratio and Fractional Flow Reserve Measurements in Stable Coronary Artery Disease and Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2018, 11, 1437-1449.	2.9	111
33	Noninvasive Diagnosis of Ischemia-Causing Coronary Stenosis Using CT Angiography. JACC: Cardiovascular Imaging, 2012, 5, 1088-1096.	5.3	108
34	Four-Year Follow-Up of TYPHOON (Trial to Assess the Use of the CYPHer Sirolimus-Eluting Coronary) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Interventions, 2011, 4, 14-23.	2.9	107
35	A Randomized Comparison of Paclitaxel-Eluting Stents Versus Bare-Metal Stents for Treatment of Unprotected Left Main Coronary Artery Stenosis. Journal of the American College of Cardiology, 2007, 50, 491-497.	2.8	103
36	Coronary bifurcation lesions treated with simple or complex stenting: 5-year survival from patient-level pooled analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study. European Heart Journal, 2016, 37, 1923-1928.	2.2	103

#	Article	IF	Citations
37	Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovascular Diabetology, 2015, 14, 133.	6.8	101
38	Derivation and Validation of a Chronic Total Coronary Occlusion Intervention Procedural Success Score From the 20,000-Patient EuroCTO Registry. JACC: Cardiovascular Interventions, 2019, 12, 335-342.	2.9	99
39	Prognostic Value and Risk Continuum of Noninvasive Fractional Flow Reserve Derived from Coronary CT Angiography. Radiology, 2019, 292, 343-351.	7.3	89
40	Heparin-Coated Stent Placement for the Treatment of Stenoses in Small Coronary Arteries of Symptomatic Patients. Circulation, 2003, 107, 1265-1270.	1.6	87
41	Effect of image quality on diagnostic accuracy of noninvasive fractional flow reserve: Results from the prospective multicenter international DISCOVER-FLOW study. Journal of Cardiovascular Computed Tomography, 2012, 6, 191-199.	1.3	87
42	Usefulness of Noninvasive Fractional Flow Reserve Computed from Coronary Computed Tomographic Angiograms for Intermediate Stenoses Confirmed by Quantitative Coronary Angiography. American Journal of Cardiology, 2012, 110, 971-976.	1.6	85
43	A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. European Heart Journal, 2015, 36, 434-439.	2.2	80
44	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention for Ostial/Mid-Shaft Lesions Versus Distal Bifurcation Lesions in Unprotected LeftÂMain Coronary Artery. JACC: Cardiovascular Interventions, 2013, 6, 1242-1249.	2.9	75
45	Projected Costs and Consequences of Computed Tomographyâ€Determined Fractional Flow Reserve. Clinical Cardiology, 2013, 36, 743-748.	1.8	71
46	Side branch fractional flow reserve measurements after main vessel stenting: a Nordic-Baltic Bifurcation Study III substudy. EuroIntervention, 2012, 7, 1155-1161.	3.2	59
47	Treatment of Heart Failure With Associated Functional Mitral RegurgitationÂUsing the ARTO System. JACC: Cardiovascular Interventions, 2015, 8, 1095-1104.	2.9	57
48	Safety in simple versus complex stenting of coronary artery bifurcation lesions. The Nordic Bifurcation Study 14-month follow-up results. EuroIntervention, 2008, 4, 229-233.	3.2	56
49	Clinical Outcome After Crush Versus Culotte Stenting of Coronary Artery Bifurcation Lesions. JACC: Cardiovascular Interventions, 2013, 6, 1160-1165.	2.9	51
50	Intravascular ultrasound to guide left main stem intervention: a NOBLE trial substudy. EuroIntervention, 2020, 16, 201-209.	3.2	48
51	Analysis of Stroke Occurring in the SYNTAX Trial Comparing Coronary Artery Bypass Surgery and Percutaneous Coronary Intervention in the Treatment of Complex Coronary Artery Disease. JACC: Cardiovascular Interventions, 2013, 6, 344-354.	2.9	46
52	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Ostial/Midshaft Lesions in Unprotected Left Main Coronary Artery From the DELTA Registry. JACC: Cardiovascular Interventions, 2014, 7, 354-361.	2.9	45
53	1-Year Results of the REMEDEEÂRegistry. JACC: Cardiovascular Interventions, 2016, 9, 1127-1134.	2.9	45
54	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European Heart Journal, 2019, 40, 2801-2809.	2.2	45

#	Article	IF	Citations
55	The SABRE Trial (Sirolimus Angioplasty Balloon forÂCoronary In-Stent Restenosis). JACC: Cardiovascular Interventions, 2017, 10, 2029-2037.	2.9	43
56	Prevalence of Helicobacter pylori infection and atrophic gastritis in Latvia. European Journal of Gastroenterology and Hepatology, 2012, 24, 1410-1417.	1.6	41
57	The DELTA 2 Registry. JACC: Cardiovascular Interventions, 2017, 10, 2401-2410.	2.9	41
58	Design and rationale for the I nfluenza vaccination A fter M yocardial I nfarction (IAMI) trial. A registry-based randomized clinical trial. American Heart Journal, 2017, 189, 94-102.	2.7	39
59	Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology. European Heart Journal, 2021, 42, 4536-4549.	2.2	37
60	9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System. JACC: Cardiovascular Interventions, 2017, 10, 160-167.	2.9	35
61	Clinical Events After Deferral of LADÂRevascularization Following PhysiologicalÂCoronaryÂAssessment. Journal of the American College of Cardiology, 2019, 73, 444-453.	2.8	35
62	Real-world experience with a novel biodegradable polymer sirolimus-eluting stent: twelve-month results of the BIOFLOW-III registry. EuroIntervention, 2016, 11, 1106-1110.	3.2	35
63	Followâ€up of the patients after stem cell transplantation for pediatric dilated cardiomyopathy. Pediatric Transplantation, 2013, 17, 266-270.	1.0	34
64	Randomised comparison of provisional side branch stenting versus a two-stent strategy for treatment of true coronary bifurcation lesions involving a large side branch: the Nordic-Baltic Bifurcation Study IV. Open Heart, 2020, 7, e000947.	2.3	34
65	Computed tomography versus invasive coronary angiography: design and methods of the pragmatic randomised multicentre DISCHARGE trial. European Radiology, 2017, 27, 2957-2968.	4.5	33
66	Mid-term outcomes after percutaneous interventions in coronary bifurcations. International Journal of Cardiology, 2019, 283, 78-83.	1.7	33
67	Comparison of early and late results of a Carbofilm-coated stent versus a pure high-grade stainless steel stent (the Carbostent-Trial). American Journal of Cardiology, 2004, 93, 1351-1356.	1.6	32
68	Percutaneous ventricular restoration (PVR) therapy using the Parachute device in 100 subjects with ischaemic dilated heart failure: one-year primary endpoint results of PARACHUTE III, a European trial. EuroIntervention, 2015, 11, 710-717.	3.2	31
69	Intravascular ultrasound assessed incomplete stent apposition and stent fracture in stent thrombosis after bare metal versus drug-eluting stent treatment the Nordic Intravascular Ultrasound Study (NIVUS). International Journal of Cardiology, 2013, 168, 1010-1016.	1.7	27
70	Long-Term Outcomes of Percutaneous Coronary Interventions or Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease in Octogenarians (from a Drug-Eluting stent for LefT main) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1	1.6	26
71	Computing Methods for Composite ClinicalÂEndpoints in Unprotected Left Main Coronary Artery Revascularization. JACC: Cardiovascular Interventions, 2016, 9, 2280-2288.	2.9	26
72	Sex Differences in Instantaneous Wave-Free Ratio or Fractional Flow Reserveâ€“Guided Revascularization Strategy. JACC: Cardiovascular Interventions, 2019, 12, 2035-2046.	2.9	26

#	Article	IF	Citations
73	Comparison of Major Adverse Cardiac Events Between Instantaneous Wave-Free Ratio and Fractional Flow Reserveâ€“Guided Strategy in Patients With or Without Type 2 Diabetes. JAMA Cardiology, 2019, 4, 857.	6.1	25
74	Treatment of Knee Osteoarthritis with Bone Marrowâ€“Derived Mononuclear Cell Injection: 12-Month Follow-up. Cartilage, 2019, 10, 26-35.	2.7	25
75	Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey. International Journal of Cardiology, 2018, 272, 20-25.	1.7	24
76	Additive diagnostic value of atherosclerotic plaque characteristics to non-invasive FFR for identification of lesions causing ischaemia: results from a prospective international multicentre trial. EuroIntervention, 2016, 12, 473-481.	3.2	24
77	Use of intravascular imaging in managing coronary artery disease. World Journal of Cardiology, 2014, 6, 393.	1.5	23
78	Intramyocardial administration of autologous bone marrow mononuclear cells in a critically ill child with dilated cardiomyopathy. Cardiology in the Young, 2011, 21, 110-112.	0.8	22
79	Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study. European Journal of Epidemiology, 2019, 34, 247-258.	5.7	22
80	Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDLâ€“C levels in a latvian population. BMC Medical Genetics, 2015, 16, 86.	2.1	21
81	The comparison of knee osteoarthritis treatment with single-dose bone marrow-derived mononuclear cells vs. hyaluronic acid injections. Medicina (Lithuania), 2017, 53, 101-108.	2.0	21
82	1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent. JACC: Cardiovascular Interventions, 2018, 11, 1969-1978.	2.9	21
83	One year clinical outcomes in patients with insulin-treated diabetes mellitus and non-insulin-treated diabetes mellitus compared to non-diabetics after deployment of the bio-engineered COMBO stent. International Journal of Cardiology, 2017, 226, 60-64.	1.7	20
84	A multicentre, prospective, randomised controlled trial to assess the safety and effectiveness of cooling as an adjunctive therapy to percutaneous intervention in patients with acute myocardial infarction: the COOL AMI EU Pivotal Trial. EuroIntervention, 2021, 17, 466-473.	3.2	18
85	Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. EuroIntervention, 2016, 12, e623-e631.	3.2	17
86	Pacemakerâ€Mediated Programmable Hypertension Control Therapy. Journal of the American Heart Association, 2017, 6, .	3.7	16
87	Single nucleotide polymorphisms of the purinergic 1 receptor are not associated with myocardial infarction in a Latvian population. Molecular Biology Reports, 2012, 39, 1917-1925.	2.3	15
88	Intravascular ultrasound assessment of minimum lumen area and intimal hyperplasia in in-stent restenosis after drug-eluting or bare-metal stent implantation. The Nordic Intravascular Ultrasound Study (NIVUS). Cardiovascular Revascularization Medicine, 2017, 18, 577-582.	0.8	15
89	Coronary guidewires. EuroIntervention, 2010, 6, 168-169.	3.2	15
90	Comparison of Percutaneous Coronary Intervention (With Drug-Eluting Stents) Versus Coronary Artery Bypass Grafting in Women With Severe Narrowing of the Left Main Coronary Artery (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Cardiology, 2014, 113, 1348-1355.	1.6	14

#	Article	IF	Citations
91	Primary endpoint results of the OMEGA Study: One-year clinical outcomes after implantation of a novel platinum chromium bare metal stent. Cardiovascular Revascularization Medicine, 2015, 16, 65-69.	0.8	14
92	Health-related qualify of life, angina type and coronary artery disease in patients with stable chest pain. Health and Quality of Life Outcomes, 2020, 18, 140.	2.4	14
93	Randomised comparison of a biodegradable polymer ultra-thin sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients with de novo native coronary artery lesions: the meriT-V trial. EuroIntervention, 2018, 14, e1207-e1214.	3.2	14
94	Nitric Oxide Production and Arachidonic Acid Metabolism in Platelet Membranes of Coronary Heart Disease Patients with and without Diabetes. Medical Principles and Practice, 2003, 12, 10-16.	2.4	13
95	Extended followâ€up safety and effectiveness of the Endeavor zotarolimusâ€eluting stent in realâ€world clinical practice: Twoâ€year followâ€up from the Eâ€Five Registry. Catheterization and Cardiovascular Interventions, 2011, 77, 993-1000.	1.7	13
96	iMap intravascular ultrasound evaluation of culprit and non-culprit lesions in patients with ST-elevation myocardial infarction. Cardiovascular Revascularization Medicine, 2013, 14, 71-75.	0.8	13
97	Evaluation of clinical outcomes after C<scp>OMBO</scp> stent treatment in patients presenting with acute coronary syndrome. Catheterization and Cardiovascular Interventions, 2017, 90, E31-E37.	1.7	13
98	Two-year clinical outcomes of patients treated with the dual-therapy stent in a 1000 patient all-comers registry. Open Heart, 2017, 4, e000634.	2.3	13
99	Intravascular Ultrasound-based Imaging Modalities for Tissue Characterisation. Interventional Cardiology Review, 2014, 9, 151.	1.6	13
100	Five-Year Results of the Bioflow-III Registry: Real-World Experience with a Biodegradable Polymer Sirolimus-Eluting Stent. Cardiovascular Revascularization Medicine, 2020, 21, 63-69.	0.8	12
101	Prevalence estimation of celiac disease in the general adult population of Latvia using serology and HLA genotyping. United European Gastroenterology Journal, 2015, 3, 190-199.	3.8	11
102	New insight to estimate under-expansion after stent implantation on bifurcation lesions using optical coherence tomography. International Journal of Cardiovascular Imaging, 2017, 33, 1677-1684.	1.5	11
103	Latvian registry of familial hypercholesterolemia: The first report of three-year results. Atherosclerosis, 2018, 277, 347-354.	0.8	11
104	Pre-operative Diagnosis of Silent Coronary Ischaemia May Reduce Post-operative Death and Myocardial Infarction and Improve Survival of Patients Undergoing Lower Extremity Surgical Revascularisation. European Journal of Vascular and Endovascular Surgery, 2020, 60, 411-420.	1.5	11
105	Transcatheter reshaping of the mitral annulus in patients with functional mitral regurgitation: one-year outcomes of the MAVERIC trial. EuroIntervention, 2021, 16, 1106-1113.	3.2	11
106	Clinical pre-test probability for obstructive coronary artery disease: insights from the European DISCHARGE pilot study. European Radiology, 2021, 31, 1471-1481.	4.5	10
107	Pepsinogen Test for the Evaluation of Precancerous Changes in Gastric Mucosa: a Population-Based Study. Journal of Gastrointestinal and Liver Diseases, 2019, 27, 11-17.	0.9	10
108	The Arto transcatheter mitral valve repair system. EuroIntervention, 2015, 14, W47-W48.	3.2	9

#	Article	IF	Citations
109	Treatment of Secondary Mitral Regurgitation in Chronic Heart Failure. Journal of the American College of Cardiology, 2017, 70, 2834-2835.	2.8	8
110	Roadmap for cardiovascular education across the European Society of Cardiology: inspiring better knowledge and skills, now and for the future. European Heart Journal, 2019, 40, 1728-1738.	2.2	8
111	Threeâ€year clinical outcomes after dualâ€therapy COMBO stent placement: Insights from the REMEDEE registry. Catheterization and Cardiovascular Interventions, 2019, 94, 342-347.	1.7	8
112	Lower ST-elevation myocardial infarction incidence during COVID-19 epidemic in Northern Europe. Scandinavian Cardiovascular Journal, 2020, 54, 358-360.	1.2	8
113	PacemakerâBased Cardiac Neuromodulation Therapy in Patients With Hypertension: A Pilot Study. Journal of the American Heart Association, 2021, 10, e020492.	3.7	8
114	Homocysteine, Î’ Vitamins and Immune Activation in Coronary Heart Disease. Pteridines, 2003, 14, 82-87.	0.5	8
115	Association between increased serum neopterin and homocysteine concentrations as well as pyridoxal-5-phosphate deficiency in patients with coronary heart disease. Pteridines, 2001, 12, 130-134.	0.5	7
116	Pilot study of safety and efficacy of polyprenols in combination with coenzyme Q10 in patients with statin-induced myopathy. Medicina (Lithuania), 2016, 52, 171-179.	2.0	7
117	Ischemic Myocardial Burden Subtended by Computed Tomographyâ€“Derived Fractional Flow Reserve (APPROACHFFRCT). JACC: Cardiovascular Imaging, 2020, 13, 2264-2267.	5.3	7
118	Diagnosis and management of silent coronary ischemia in patients undergoing carotid endarterectomy. Journal of Vascular Surgery, 2021, 73, 533-541.	1.1	7
119	Twoâ€year outcomes from the MitrAl ValvE Re palr Clinical (MAVERIC) trial: a novel percutaneous treatment of functional mitral regurgitation. European Journal of Heart Failure, 2021, 23, 1775-1783.	7.1	7
120	Prognostic Value of Tryptophan Load Test Followed by Serum Kynurenine Determination. Itâ€™s Comparison With Pyridoxal-5-phosphate, Kynurenine, Homocysteine and Neopterin Amounts. Advances in Experimental Medicine and Biology, 2003, 527, 307-315.	1.6	7
121	A Population-Based Cross-Sectional Study of Cardiovascular Risk Factor in Latvia. Medicina (Lithuania), 2012, 48, 46.	2.0	6
122	Prevalence of dyslipidemia in statin-treated patients in the Baltic states (Estonia, Latvia, and Lithuania): Results of the Dyslipidemia International Study (DYSIS). Medicina (Lithuania), 2014, 50, 44-53.	2.0	6
123	Management of coronary artery disease patients in Latvia compared with practice in Central-Eastern Europe and globally: Analysis of the CLARIFY registry. Medicina (Lithuania), 2015, 51, 240-246.	2.0	6
124	Final fiveâ€year results of the REMEDEE Registry: Realâ€world experience with the dualâ€therapy COMBO stent. Catheterization and Cardiovascular Interventions, 2020, 98, 503-510.	1.7	6
125	Comparison of outcome between blood culture positive and negative infective endocarditis patients undergoing cardiac surgery. Journal of Cardiothoracic Surgery, 2021, 16, 147.	1.1	6
126	Technical aspects of the culotte technique. EuroIntervention, 2015, 11, V99-V101.	3.2	6

#	Article	IF	Citations
127	Circulating plasma microRNA-126, microRNA-145, and microRNA-155 and their association with atherosclerotic plaque characteristics. Journal of Clinical and Translational Research, 2020, 5, 60-67.	0.3	6
128	A population-based cross-sectional study of cardiovascular risk factor in Latvia. Medicina (Lithuania), 2012, 48, 310-6.	2.0	6
129	Coronary revascularization of patients with silent coronary ischemia may reduce the risk of myocardial infarction and cardiovascular death after carotid endarterectomy. Journal of Vascular Surgery, 2022, 76, 750-759.	1.1	6
130	Three-Dimensional Fourier-Domain Optical Coherence Tomography Imaging: Advantages and Future Development. Current Cardiovascular Imaging Reports, 2012, 5, 221-230.	0.6	5
131	Usefulness of Neopterin, C-reactive Protein, Homocysteine, Pyridoxal-5-phosphate, and Phospholipid Determination in Coronary Artery Disease. Pteridines, 2005, 16, 15-21.	0.5	4
132	New-generation drug-eluting stents for left main coronary artery disease according to the EXCEL trial enrollment criteria: Insights from the all-comers, international, multicenter DELTA-2 registry. International Journal of Cardiology, 2019, 280, 30-37.	1.7	4
133	The Full Revasc (Ffr-gUidance for compLete non-cuLprit REVASCularization) Registry-based randomized clinical trial. American Heart Journal, 2021, 241, 92-100.	2.7	4
134	Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES. Canadian Journal of Cardiology, 2022, 38, 1542-1549.	1.7	4
135	Insufficient control of heart rate in stable coronary artery disease patients in Latvia. Medicina (Lithuania), 2014, 50, 295-302.	2.0	3
136	Role of genetic factors on the effect of additional loading doses and two maintenance doses used to overcome clopidogrel hyporesponsiveness. Medicina (Lithuania), 2014, 50, 19-27.	2.0	3
137	New-Generation Drug-Eluting Stents forÂLeft Main In-Stent Restenosis. JACC: Cardiovascular Interventions, 2018, 11, 2438-2440.	2.9	3
138	Long-Term Performance of the COMBO Dual-Therapy Stent: Results from the REMEDEE Registry. Cardiovascular Revascularization Medicine, 2020, 21, 567-570.	0.8	3
139	A common promoter variant of the gene encoding cyclooxygenase-1 (PTGS1) is related to decreased incidence of myocardial infarction in patients with coronary artery disease. Thrombosis Research, 2011, 127, 600-602.	1.7	2
140	Are Paclitaxel-Eluting Stents Better in Unprotected Left Main Coronary Artery Disease? Three-Year Clinical and Intravascular Imaging Results From a Randomized Study. Medicina (Lithuania), 2011, 47, 77.	2.0	2
141	Decrease in annual incidence of acute coronary syndrome and restructuring of coronary care in Latvia. Cor Et Vasa, 2014, 56, e325-e332.	0.1	2
142	Cardiac computed tomography assessment of the near term impact of percutaneous ventricular restoration therapy (parachute^{Â®}) on mitral valve geometry. Catheterization and Cardiovascular Interventions, 2016, 88, E45-51.	1.7	2
143	Lead-Related Infective Endocarditis in Latvia: A Single Centre Experience. Medicina (Lithuania), 2019, 55, 566.	2.0	2
144	Coronary artery bypass graft versus percutaneous coronary intervention with drug-eluting stent implantation for diabetic patients with unprotected left main coronary artery disease: the D-DELTA registry. EuroIntervention, 2013, 9, 803-808.	3.2	2

#	Article	IF	Citations
145	Five year clinical outcomes of the COBRA Polyzene F NanoCoated Coronary Stent System. Cardiovascular Revascularization Medicine, 2022, , .	0.8	2
146	Comparing the sensitivity of pyridoxal-5-phosphate, homocysteine and neopterin in coronary heart disease. Pteridines, 2002, 13, 100-102.	0.5	1
147	Inflammation, Homocysteine, Pyridoxal-5-phosphate and Lipids in Patients with Coronary Artery Disease before and Six Months after Coronary Angioplasty Followed by Stent Implantation. Pteridines, 2005, 16, 190-194.	0.5	1
148	Intravascular Ultrasound Data and Results of Serum Biochemical Indices at the Time of Stenting and after Six Months in Patients with Coronary Artery Disease. Pteridines, 2006, 17, 95-99.	0.5	1
149	Evaluating the quality of implantation of percutaneous ventricular restoration device (ParachuteÂ®) by cardiac computed tomography. Catheterization and Cardiovascular Interventions, 2017, 89, E104-E111.	1.7	1
150	Two-year clinical outcomes after implantation of an everolimus-eluting bioresorbable scaffold (Absorb) in stable angina and acute coronary syndrome patients. Single-centre real-life registry data. Postepy W Kardiologii Interwencyjnej, 2018, 14, 144-148.	0.2	1
151	Lessons for the treatment of bifurcation lesions: from nowadays to the future. Interventional Cardiology, 2011, 3, 55-65.	0.0	1
152	A case report of pulmonary vein isolation performed in a patient with polysplenia and interrupted inferior vena cava. European Heart Journal - Case Reports, 2021, 5, ytab480.	0.6	1
153	Impact of dual antiplatelet therapy duration on clinical outcome after coronary bifurcation stenting: results from the Euro Bifurcation Club registry. Panminerva Medica, 2022, , .	0.8	1
154	Relation of the Leu40Arg variant of glycoprotein IIIA to personal and family history of myocardial infarction. Proceedings of the Latvian Academy of Sciences, 2009, 63, 100-103.	0.1	0
155	Healthy Alternatives of the Mediterranean Diet in Latvia. Proceedings of the Latvian Academy of Sciences, 2013, 67, 315-319.	0.1	0
156	Response to Letter Regarding Article, â€œNoninvasive Fractional Flow Reserve Derived From Computed Tomography Angiography for Coronary Lesions of Intermediate Stenosis Severity: Results From the DeFACTO Studyâ€• Circulation: Cardiovascular Imaging, 2014, 7, 571-571.	2.6	0
157	Plaque and blood vulnerability in ST segment elevation myocardial infarction patients. Coronary Artery Disease, 2014, 25, 104-110.	0.7	0
158	In-vivo iMap IVUS comparison of in-stent neointima and native coronary atherosclerosis. Cardiovascular Revascularization Medicine, 2015, 16, 233-236.	0.8	0
159	Evaluation Of Massive Parallel Sequencing As A Diagnostic Tool For Familial Hypercholesterolemia. Proceedings of the Latvian Academy of Sciences, 2015, 69, 1-7.	0.1	0
160	Carotid artery stenting outcomes in high-risk patients receiving best medical therapy: results from a single high-volume interventional cardiology practice. Cor Et Vasa, 2016, 58, e569-e575.	0.1	0
161	Comparison of Intravascular Imaging and Quantitative Coronary Angiography to Evaluate Neointimal Proliferation after Complex Lesion Stenting. Proceedings of the Latvian Academy of Sciences, 2009, 63, 168-173.	0.1	0
162	Control of Resting Heart Rate and Other Risk Factors Over a Three-year Period in Outpatients with Stable Coronary Artery Disease in Latvia. Proceedings of the Latvian Academy of Sciences, 2014, 67, 457-465.	0.1	0

#	Article	IF	Citations
163	Transcatheter Vs. Surgical Closure of Atrial Septal Defects in Adults. Proceedings of the Latvian Academy of Sciences, 2018, 72, 16-22.	0.1	0
164	Original paper: A new type of polyphenols-containing dietary supplement for correction of lipids and inflammatory markers in patients with coronary artery disease. Seminars in Cardiovascular Medicine, 2018, 24, 22-28.	0.3	0
165	Second European Cardiac Resynchronisation Therapy Survey (Crt Survey Ii): Latvian Data Compared to Europe. Proceedings of the Latvian Academy of Sciences, 2020, 74, 358-365.	0.1	0
166	Exercise, Chronotropic and Inotropic Capacity in Athletes with Different Training Programmes. Proceedings of the Latvian Academy of Sciences, 2020, 74, 18-24.	0.1	0
167	Thirty Years of Epidemiological Studies of Cardiovascular Disease Risk Factors in Latvia: Why are they Needed?. Proceedings of the Latvian Academy of Sciences, 2020, 74, 299-307.	0.1	0
168	Plasma circulating microRNAs in patients with stable coronary artery disease - Impact of different cardiovascular risk profiles and glomerular filtration rates. Journal of Clinical and Translational Research, 2021, 7, 270-276.	0.3	0
169	What Is Hidden Behind Yellow Pixels: from Pathology to Intravascular Imaging of Atherosclerotic Plaque. Current Atherosclerosis Reports, 2022, 24, 97.	4.8	0
170	Risk factors associated with mortality in the infective endocarditis patients requiring cardiac surgery: a study based on Latvian population. Journal of Cardiovascular Surgery, 2022, , .	0.6	0
171	Comparative Analysis of the Most Important Cardiovascular Risk Factors Based on Cross-Sectional Studies in the Population of Latvia. Medicina (Lithuania), 2022, 58, 643.	2.0	0